Correction to: British Journal of Cancer 10.1038/s41416-020-01255-z, published online 16 February 2021
After publication of our article [1] we became aware that the Competing Interests statement was incomplete. It should read as follows: “C.F.W. is a consultant/advisory board member for Mylan Inc. A.F.-A. is a paid employee of Mylan Inc. and may hold stock with the company. J.M. is a paid employee of Mylan Healthcare GmbH in Hannover, Germany, and may hold stock with the company. Mylan Inc. produces trastuzumab for intravenous administration.”
The original article has been corrected.
Reference
- 1.Waller CF, Möbius J, Fuentes-Alburo A. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. Br J Cancer. 2021;124:1346–52. 10.1038/s41416-020-01255-z 10.1038/s41416-020-01255-z [DOI] [PMC free article] [PubMed] [Google Scholar]